Related references
Note: Only part of the references are listed.The current approach of the Epilepsy Therapy Screening Program contract site for identifying improved therapies for the treatment of pharmacoresistant seizures in epilepsy
Karen S. Wilcox et al.
NEUROPHARMACOLOGY (2020)
Antipyretic, anti-inflammatory and analgesic activities of Periplaneta americana extract and underlying mechanisms
Tienthanh Nguyen et al.
BIOMEDICINE & PHARMACOTHERAPY (2020)
Pregabalin for neuropathic pain in adults
Sheena Derry et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2019)
Evaluation of anticonvulsant and analgesic activity of new hybrid compounds derived from N-phenyl-2-(2,5-dioxopyrrolidin-l-yl)-propanamides and -butanamides
Anna Rapacz et al.
EPILEPSY RESEARCH (2018)
Antiallodynic and antihyperalgesic activity of new 3,3-diphenyl-propionamides with anticonvulsant activity in models of pain in mice
Anna Rapacz et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2018)
Treatment Outcomes in Patients With Newly Diagnosed Epilepsy Treated With Established and New Antiepileptic Drugs A 30-Year Longitudinal Cohort Study
Zhibin Chen et al.
JAMA NEUROLOGY (2018)
Pharmacotherapy for Focal Seizures in Children and Adolescents
Clare E. Stevens et al.
DRUGS (2018)
Operational classification of seizure types by the International League Against Epilepsy: Position Paper of the ILAE Commission for Classification and Terminology
Robert S. Fisher et al.
EPILEPSIA (2017)
Neuropathic pain
Luana Colloca et al.
NATURE REVIEWS DISEASE PRIMERS (2017)
Anticonvulsant and antinociceptive activity of new amides derived from 3-phenyl-2,5-dioxo-pyrrolidine-1-yl-acetic acid in mice
Anna Rapacz et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2016)
Design, synthesis and biological evaluation of new hybrid anticonvulsants derived from N-benzyl-2-(2,5-dioxopyrrolidin-1-yl)propanamide and 2-(2,5-dioxopyrrolidin-1-yl)butanamide derivatives
Krzysztof Kaminski et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2015)
In vitro models for neurotoxicology research
Daniel Jose Barbosa et al.
TOXICOLOGY RESEARCH (2015)
Genetic background of mice strongly influences treatment resistance in the 6 Hz seizure model
Karine Leclercq et al.
EPILEPSIA (2015)
Oral Druggable Space beyond the Rule of 5: Insights from Drugs and Clinical Candidates
Bradley Croy Doak et al.
CHEMISTRY & BIOLOGY (2014)
Effects of WIN 55,212-2 (a non-selective cannabinoid CB1 and CB2 receptor agonist) on the protective action of various classical antiepileptic drugs in the mouse 6 Hz psychomotor seizure model
Magdalena Florek-Luszczki et al.
JOURNAL OF NEURAL TRANSMISSION (2014)
In vitro models for liver toxicity testing
Valerie Y. Soldatow et al.
TOXICOLOGY RESEARCH (2013)
Softening the Rule of Five-where to draw the line?
Joachim Petit et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2012)
Synthesis and anticonvulsant activity of new N-Mannich bases derived from 5-cyclopropyl-5-phenyl- and 5-cyclopropyl-5-(4-chlorophenyl)-imidazolidine-2,4-diones
Hanna Byrtus et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2011)
Synthesis and Anticonvulsant Properties of New Mannich Bases Derived from 3-Aryl-pyrrolidine-2,5-diones. Part 1
Jolanta Obniska et al.
ARCHIV DER PHARMAZIE (2010)
Lacosamide: A review of preclinical properties
Bettina K. Beyreuther et al.
CNS DRUG REVIEWS (2007)
Comparison of antiepileptic drugs tiagabine, lamotrigine, and gabapentin in mouse models of acute, prolonged, and chronic nociception
TM Laughlin et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2002)
Molecular properties that influence the oral bioavailability of drug candidates
DF Veber et al.
JOURNAL OF MEDICINAL CHEMISTRY (2002)
Share Paper
